Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

ClinicalTrials.gov ID: NCT04279769

Public ClinicalTrials.gov record NCT04279769. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 29, 2026, 9:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase 1b multiple ascending dose escalation study to evaluate the safety and tolerability of arginase inhibitor CB-280 in subjects with cystic fibrosis.

Study identification

NCT ID: NCT04279769
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Calithera Biosciences, Inc; Industry
Enrollment: 32 participants

Conditions and interventions

Conditions

Cystic Fibrosis

Interventions

CB-280 Drug
Placebos Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 2, 2020
Primary completion: Nov 22, 2021
Completion: Nov 22, 2021
Last update posted: Apr 12, 2022

2020 – 2021

United States locations

U.S. sites: 17
U.S. states: 17
U.S. cities: 17

Facility	City	State	ZIP	Site status
University of Arkansas for Medical Sciences	Little Rock	Arkansas	72205	—
Long Beach Memorial Medical Center	Long Beach	California	90806	—
University of Florida	Gainesville	Florida	32610	—
The Cystic Fibrosis Institute	Glenview	Illinois	60025	—
Indiana University	Indianapolis	Indiana	46202	—
University of Kansas Medical Center	Kansas City	Kansas	66160	—
Johns Hopkins University	Baltimore	Maryland	21287	—
Boston Children's Hospital, Brigham & Women's Hospital	Boston	Massachusetts	02115	—
Billings Clinic	Billings	Montana	59101	—
New York Medical College at Westchester Medical Center	Hawthorne	New York	10532	—
UNC Marsico Clinical Research Center	Chapel Hill	North Carolina	27514	—
University Hospitals Cleveland Medical Center	Cleveland	Ohio	44106	—
Hershey Medical Center Pennsylvania State University	Hershey	Pennsylvania	17033	—
Medical University of South Carolina	Charleston	South Carolina	29425	—
University of Utah	Salt Lake City	Utah	84132	—
Vermont Lung Center at the University of Vermont Medical Center	Colchester	Vermont	05446	—
Virginia Commonwealth University	Richmond	Virginia	23219	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04279769, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 12, 2022 · Synced Sep 29, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04279769 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →